FSPTX
Price
$32.48
Change
-$0.86 (-2.58%)
Updated
Sep 6 closing price
PTTEX
Price
$69.85
Change
-$1.77 (-2.47%)
Updated
Sep 6 closing price
Ad is loading...

FSPTX vs PTTEX

Header iconFSPTX vs PTTEX Comparison
Open Charts FSPTX vs PTTEXBanner chart's image
Fidelity Select Technology
Price$32.48
Change-$0.86 (-2.58%)
VolumeN/A
CapitalizationN/A
Putnam Global Technology R6
Price$69.85
Change-$1.77 (-2.47%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FSPTX vs PTTEX Comparison Chart
Loading...
VS
FSPTX vs. PTTEX commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSPTX is a Buy and PTTEX is a Buy.

FUNDAMENTALS
Fundamentals
FSPTX has more cash in the bank: 15.8B vs. PTTEX (1.21B). PTTEX pays higher dividends than FSPTX: PTTEX (0.58) vs FSPTX (0.01). FSPTX was incepted earlier than PTTEX: FSPTX (43 years) vs PTTEX (6 years). PTTEX is a more actively managed with annual turnover of: 57.00 vs. FSPTX (24.00). FSPTX (0) and PTTEX (0) have matching initial minimum investment requirements. PTTEX annual gain was more profitable for investors over the last year : 30.24 vs. FSPTX (25.24). FSPTX (87.80) and PTTEX (84.07) have equivalent 5 years return.
FSPTXPTTEXFSPTX / PTTEX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence43 years6 years-
Gain YTD16.94117.77795%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets15.8B1.21B1,305%
Annual Yield % from dividends0.010.582%
Returns for 1 year25.2430.2483%
Returns for 3 years11.48-3.45-333%
Returns for 5 years87.8084.07104%
Returns for 10 years166.53N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
YEXT5.560.64
+13.01%
Yext
CNO34.25-0.23
-0.67%
CNO Financial Group
MANH252.82-3.96
-1.54%
Manhattan Associates
BRTX1.55-0.08
-4.91%
BioRestorative Therapies
CNTX2.28-0.15
-6.17%
Context Therapeutics